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Abstract
 Background—Quantifying tissue drug concentrations can yield important information during 
drug development, but complicates pharmacokinetic study design. Mucosal fluids collected by 
direct aspiration(cervicovaginal fluid; CVF) or swab(rectal fluid; RF) might be used as tissue 
concentration surrogates, but these relationships are not well characterized.
 Methods—Forty-nine healthy women, given a single oral dose of tenofovir, maraviroc, 
emtricitabine, or raltegravir at 50% to 200% of the treatment dose, provided 13 plasma, 12 CVF, 
12 RF and one cervical, vaginal and rectal tissue biopsy over 48hrs. Relationships between these 
paired samples were characterized by linear and multiple linear regression. Adjusted r2 values 
were used to select the final predictive models.
 Results—CVF exposure increased linearly with dose for all antiretrovirals (r2≥0.23, p≤0.02) 
except raltegravir (r2=0.08, p=0.19). In RF, only emtricitabine increased linearly with dose 
(r2=0.27, p=0.01). For all antiretrovirals, CVF and RF concentrations significantly correlated with 
mucosal tissue concentrations (female genital tract r2≥0.37, rectal tissue r2≥0.50; p≤0.001). In the 
final multivariate models, plasma and fluid concentrations were both associated with FGT 
concentrations for all antiretrovirals (r2≥0.81; p<0.001). The same was noted for rectal tissue 
(r2≥0.58; p<0.001) except for tenofovir, for which RF alone was predictive of tissue concentration 
(r2=0.91; p<0.001).
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 Conclusions—Mucosal fluids were positively correlated with tissue concentrations, and 
including plasma concentrations improved the regression models in most cases. Dose linearity in 
CVF, but not RF, suggests a saturation process in lower gastrointestinal tract tissue. These findings 
suggest that mucosal fluid and plasma concentrations may be used for qualitative inference of 
tissue concentrations for these antiretrovirals.
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 Introduction
Current HIV pre-exposure prophylaxis (PrEP) strategies rely upon antiretrovirals to protect 
uninfected HIV target cells in tissues such as the genital and lower gastrointestinal tracts.1 
However, antiretroviral penetration into mucosal tissues is highly variable between and 
within drug class2 and not predicted by the physiochemical properties of the drug alone.3 
Thus, direct measurement of tissue concentrations is necessary.
Pharmacokinetic investigation of mucosal tissue concentrations involves invasive biopsies. 
These techniques limit the number of samples that can safely be obtained from an individual 
and require involved statistical techniques to interpret the sparsely sampled data.4 Tissue 
sampling also increases the cost and difficulty associated with sample collection, storage and 
processing for drug quantification. To circumvent these challenges, investigators have used 
mucosal fluids collected from the female genital tract by direct aspiration (cervicovaginal 
fluid; CVF) or the lower gastrointestinal tract by swab (rectal fluid; RF) as a surrogate to 
describe antiretroviral distribution into these compartments.5-9 However, to date the degree 
of association between mucosal fluid and tissue concentrations has not been well 
characterized. To determine whether accessible fluid can be used to impute tissue drug 
exposure, we conducted a robust pharmacokinetic study designed to quantify the 
relationship between drug concentrations in mucosal fluids and tissues for four 
antiretrovirals across multiple doses.
 Methods
 Trial Design
This single center, open-label, dose ranging pharmacokinetic investigation enrolled healthy, 
premenopausal female volunteers between 18 and 49 years of age with intact gastrointestinal 
and genital tracts and regular menstrual cycles. Participants were excluded if they had any 
medication allergies; clinically significant medical conditions or abnormal screening 
laboratory tests; symptomatic bacterial vaginosis; any sexually transmitted infection, HIV, or 
hepatitis B or C; were pregnant or lactating; or tested positive for any drugs of abuse. 
Participants were also excluded if they had taken any investigational drug in the last 4 
months or were not using an approved method of contraception (systemic hormonal 
contraception, IUD, bilateral tubal ligation, vasectomized male partner, condom plus 
spermicide, female only sex partners or 3 months of abstinence prior to enrollment).
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Within 45 days of screening and 7-14 days after the end of their last menstrual period, 
participants were sequentially assigned to one of two treatment arms: tenofovir disoproxil 
fumarate+maraviroc or emtricitabine+raltegravir. The treatment arms were subdivided into 
three dosing groups, which received 50, 100, or 200% of the licensed treatment doses for 
both drugs. Participants were admitted to the UNC HealthCare Clinical Trials Research 
Center (CTRC) where they received a single oral dose of tenofovir disoproxil fumarate 
(Viread; Gilead Sciences Inc, Forest City, CA) 150, 300, or 600mg with maraviroc 
(Selzentry; ViiV Healthcare, Brentford, United Kingdom) 150, 300, or 600mg, or 
emtricitabine (Emtriva; Gilead Sciences Inc.) 10mg/ml solution 10, 20, or 40ml with 
compounded raltegravir (Issentress, Merck & Co, Kenilworth, NJ) suspension 20mg/ml 10, 
20, or 40ml. At the time the study protocol was written, raltegravir tablets and emtricitabine 
capsules were only available in 400 and 200mg strengths, respectively. Liquid formulations 
were required to achieve the 50% dose. Antiretrovirals combinations were selected to avoid 
drug interactions and reduce the number of participants required for enrollment. Participants 
were asked to fast for 8 hours prior and 2 hours after medication administration. Serial blood 
samples were collected at baseline, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, and 48 hours. CVF 
and RF were obtained at 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, and 48 hours. Each participant 
provided cervical (1 biopsy), vaginal (1 biopsy), and rectal (10 biopsies) tissue samples, 
collected at 6, 12, 24, or 48 hours post-dose. Participants were placed on a low fiber diet for 
3 days prior, and a clear liquid diet for 12 hours prior to their rectal biopsy. Women were 
discharged from the CTRC after their last sample was collected and then returned for 
follow-up 7 to 10 days after their last biopsy. Safety assessments were conducted on each 
day of the in-patient visit and at the follow up visit. Safety clinical tests for all participants 
were performed at the follow-up visit. Women were screened for pregnancy at all visits.
This study was conducted in accordance with Good Clinical Practice procedures, all 
applicable regulatory requirements, and the guiding principles of the Declaration of 
Helsinki. The study protocol was approved by the Biomedical Institutional Review Board at 
the University of North Carolina at Chapel Hill. All participants provided written informed 
consent before study entry and the study was registered with clinicaltrials.gov 
(NCT01330199). Adverse events were assessed using a standard questionnaire and graded 
according to the DAIDS Adverse Events grading table.10
 Sample Collection and Processing
Identical procedures were used to obtain cervical and vaginal tissue biopsies, which were 
collected using a sterilized Baby Tischler biopsy punch (Cooper Surgical, CT, USA). Rectal 
tissue biopsies were collected using a single use-240 cm radial jaw forceps (Boston 
Scientific, MA, USA), obtained through a 19 mm × 10 cm plastic disposable anoscope. All 
tissues were immediately placed in a cryovial and snap frozen in liquid nitrogen then stored 
at −80°C. At the time of sample analysis tissue biopsies were removed from the cryovial, 
weighed, transferred to a Precellys® hard tissue grinding kit tube (Cayman Chemical, MI, 
USA), and homogenized in cold 70:30 acetonitrile:1mM ammonium phosphate buffer (pH 
7.4). Concentrations were normalized to tissue weight in grams. Whole blood was collected 
in 3 ml EDTA tubes, centrifuged at 3000 rpm for 10 minutes at 4°C, and resulting blood 
plasma was transferred to a 1.8 ml cryovial, and stored at −80°C until sample analysis. CVF 
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collected via direct aspirate (Vaginal Specimen Aspirator; CarTika) was immediately 
transferred to a cryovial and stored at −80°C until sample analysis. RF was collected via 
sterile polyester swab (Puritan Medical Products Company LLC, Guilford, MA, USA) and 
stored in a 15ml falcon tube at −80°C until sample analysis. Rectal fluid samples were 
extracted in 2 ml of 70:30 methanol:water and results were reported as ng/swab.
 Analytical Methods
HPLC-MS/MS methods were used to measure emtricitabine, maraviroc, raltegravir, and 
tenofovir in blood plasma, tissues, and mucosal fluids. The calibrated linear range of the 
analyte standard curve was 5-5000 ng/ml in plasma, 0.02-20 ng/ml in tissue homogenate, 
5-5000 ng/ml in CVF, and 0.1-100 ng/ml in RF. All samples were extracted by protein 
precipitation with stable, isotopically-labeled internal standards (13C5-tenofovir, 13C15N2-
emtricitabine, maraviroc-d6, and raltegravir-d3) added for quantification. All calibration 
standards and QCs were prepared in their respective blank matrices as follows: human 
plasma; human tissues homogenized in 70:30 acetonitrile:1mM ammonium phosphate (pH 
7.4); human CVF diluted in a 1:4 ratio with 0.9% sodium chloride; and 70:30 
methanol:water solvent for RF. Calibration standards and quality control (QC) samples met 
15% acceptance criteria for precision and accuracy. A tissue and mucosal fluid density of 
1g/ml11 was used to convert tissue and CVF concentrations into nMolar units.
 Pharmacokinetic Analysis
Non-compartmental analysis of plasma and mucosal fluid drug concentrations was 
conducted using WinNonlin software (Version 6.3; Cary, NC, USA). The linear up-log down 
trapezoidal method was used to calculate area under the concentration time curve from 0 to 
48 hours (AUC0-48hr). Because no notable differences were observed between cervical and 
vaginal tissue drug concentrations, the concentrations from these two matrices were 
averaged together for a representative female genital tract tissue concentration.
 Statistical Analysis
To describe the relationship between dose and concentration in mucosal fluids, a linear 
regression model was fit using natural log-transformed AUC0-48hr and natural log-
transformed dose. Dose proportionality was defined as an r-fold increase in dose resulting in 
an r-fold increase in concentration; therefore in this analysis, perfect dose proportionality 
was indicated by the slope of the regression line (β1) equaling 1. It was specified a priori that 
dose proportionality would be declared if the 90% confidence interval (CI) of β1 fell within 
0.64 to 1.36. Assuming %coefficient of variation (CV) ≤45%, 8 women per dosing level 
provided at least 80% power to declare dose proportionality. Linearity between dose and 
exposure was assessed by ordinary least squares regression (OLS) of the natural log-
transformed dose versus AUC0-48hr where p <0.05 indicated a statistically significant 
relationship and the r2 value demonstrated the strength of the linear relationship.
Left censoring was observed for drug concentration measurements below the lower limit of 
quantification (BLQ) or detection (BLD). Ad hoc approaches for analysis of left-censored 
data (e.g. BLQ or BLD values imputed at 0.5 or 0.1 times the lower limit of quantification 
(LLOQ), respectively) can result in biased regression coefficients and underestimated 
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standard errors.12 Therefore, multivariable linear models that appropriately accounted for 
left censoring were employed. To characterize the relationship between log10-transformed 
tissue concentration (Y), log10-transformed plasma concentration (X1), and log10-
transformed fluid concentration (X2), linear models of the form Y = b0 + b1X1 + b2X2 + ε 
were fit where ε ~ N(0, σy|x1,x22). For analyses with no censored observations, linear models 
were fit with OLS regression and the respective fluid concentration was added to the plasma 
versus tissue model in a multivariable linear regression. Following Lyles and colleagues, 
maximum likelihood was used for analyses with left censoring in Y and one X variable with 
the assumption that X and Y follow a bivariate normal distribution.12, 13 In a similar fashion, 
this left-censored linear regression (LCLR) method was extended to handle left censoring in 
two predictor variables (X1 and X2, as observed for raltegravir), under the assumption that 
X1, X2, and Y follow a multivariate normal distribution.14 To apply the LCLR method, BLQ 
observations were left censored at the LLOQ, and BLD observations were left censored at 
0.2 times the LLOQ. Adjusted r2 values were used to compare nested models incorporating 
plasma and fluid concentrations. Each tissue and antiretroviral drug was assessed separately. 
Statistical analyses were conducted in SAS (Version 9.4; Cary, North Carolina).
 Results
 Subject Demographics
Forty-nine healthy female volunteers gave written consent to be in the study. One participant 
dosed with tenofovir disoproxil fumarate 300mg and maraviroc 300mg was unable to 
provide samples and was withdrawn and replaced. One participant's samples from the 
emtricitabine/raltegravir 200/400mg dosing group were not analyzed because of improper 
storage. Therefore 47 pairs of concentration data (tenofovir disoproxil fumarate/maraviroc 
N=24; emtricitabine/raltegravir N=23) were included in subsequent regression analyses. For 
the tenofovir disoproxil fumarate/maraviroc and emtricitabine/raltegravir arms the median 
(25th, 75th percentile) age was 27 (23, 31) and 22 (21, 27) years and the median (25th, 75th 
percentile) BMI was 24.1 (21.6, 26.9) and 22.5 (20.8, 26.5) kg/m2, respectively. The 
majority of study participants in both arms were Caucasian (64% in tenofovir disoproxil 
fumarate/maraviroc and 75% for emtricitabine/raltegravir). Thirty-two percent and 17% of 
study participants were African American in the tenofovir disoproxil fumarate/maraviroc 
and emtricitabine/raltegravir groups, respectively. Single doses of these antiretrovirals up to 
200% of the licensed treatment dose were well tolerated with no adverse events greater than 
Grade 1. The most common adverse events were headache, nausea, and bowel disturbances 
occurring in 12, 4, and 4% of dosed participant, respectively. No other adverse event was 
reported by multiple study participants.
 Fluid Pharmacokinetics and Dose Linearity
Concentrations over the 48-hour sampling window for each drug are stratified by dose and 
presented in Figures 1 and 2 for CVF and RF, respectively. The median (25th, 75th 
percentile) time to maximum concentration (Tmax) in the CVF across all dosing groups was 
as follows: tenofovir=8.9 (3.9, 16.4) hours, maraviroc=7.4 (5.8, 8.9) hours, 
emtricitabine=5.8 (2.9, 8.9) hours, and raltegravir= 3.0 (2.9, 5.7) hours. At 48 hours after the 
single dose, tenofovir and maraviroc could be detected in 96% (23/24) and 100% (24/24) of 
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CVF samples, respectively; whereas emtricitabine and raltegravir could be detected in 100% 
(23/23) and 52% (12/23) of samples, respectively. We observed a delay in analyte 
distribution to RF where the median (25th, 75th percentile) Tmax was 35.9 (12.7, 44.9) hours 
for tenofovir, 24.1 (9.7, 44.9) hours for maraviroc, 24.1 (12.0, 47.9) hours for emtricitabine, 
and 23.9 (6.1, 47.8) hours for raltegravir. By 48 hours after dosing, tenofovir and maraviroc 
could be detected in 100% (24/24) of RF samples and emtricitabine and raltegravir were 
detected in 96% (22/23) of samples.
In plasma, only emtricitabine met the pre-specified definition for dose proportionality (90% 
CI β1 0.72 to 0.99; Table 1). However, we did observe a linear relationship between dose and 
exposure on a natural log scale for all analytes in plasma (r2≥0.64; p<0.001). In CVF while 
no analyte met the dose proportionality criteria, tenofovir, maraviroc and emtricitabine 
demonstrated a linear relationship between dose and exposure (r2≥0.23, p≤0.021). Finally, in 
RF no analyte met dose proportionality criteria, and only emtricitabine demonstrated a 
significant linear relationship between dose and exposure (r2=0.27, p=0.011).
 Fluid vs Tissue Drug Concentrations
Paired concentrations are plotted in Figure 3 with the female genital tract tissue vs plasma 
(left panel) or CVF (right panel) and in Figure 4 for rectal tissue vs plasma (left panel) or 
rectal fluid (right panel). We observed significant relationships between CVF and female 
genital tract tissue concentrations (adjusted r2 values≥0.37; p<0.001) as well as RF and 
rectal tissue concentration (adjusted r2≥0.50; p<0.001) for all 4 antiretrovirals. In the female 
genital tract, plasma explained more of the variability in tissue concentration compared to 
CVF (adjusted r2 range =0.71 to 0.88 vs 0.37 to 0.74, respectively). This observation was 
reversed in rectal tissue where plasma concentrations could not explain the variability in 
tissue concentrations (adjusted r2 range: −0.02 to 0.32) and mucosal fluid explained 50% or 
more of the variability in tissue concentration (adjusted r2 values range: 0.50 to 0.91). 
Combining both independent variables (plasma and mucosal fluid) into a multiple regression 
model improved the amount of explained variability in tissue concentration (as determined 
by an increase in the adjusted r2 value) for all analytes except for tenofovir in the lower 
gastrointestinal tract. Plasma tenofovir concentrations were not significantly associated with 
rectal tissue concentrations in a bivariate analysis (adjusted r2=0.002, p=0.32) and did not 
improve the adjusted r2 in a multiple linear regression analysis. Thus tenofovir plasma data 
were not included in the final model; all other final models included both plasma and fluid 
concentration. In the female genital tract the adjusted r2 value for the final regression models 
were as follows: tenofovir r2=0.81, maraviroc r2=0.92, emtricitabine r2=0.81, raltegravir 
r2=0.95. In the lower gastrointestinal tract tissue these were: tenofovir r2=0.91, maraviroc r2 
=0.80, emtricitabine r2=0.58, raltegravir r2=0.66.
 Discussion
The effectiveness of antiretroviral-based prevention may rely on achieving adequate drug 
exposure in compartments exposed to HIV during sexual transmission. Yet antiretroviral 
distribution to the genital and gastrointestinal tracts is highly variable between and within 
each class of agents.2 For this reason a thorough understanding of antiretroviral distribution 
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to mucosal tissues is required to ensure these strategies achieve adequate antiretroviral 
exposure.
Physiochemical factors that influence a drug's ability to move out of the central blood 
compartment and into the tissues include: lipophilicity, protein binding, blood perfusion, 
ionization state, molecular weight, and transporter affinity.15 Ideally, tissue penetration could 
be predicted on the basis of physiochemical properties of the drug rather than using 
expensive and cumbersome pharmacokinetic sampling. However, a recent quantitative 
structure activity relationship modeling study was unable to build an externally predictive 
model of tissue penetration due to the limited data available in the literature.3 Animal 
models (e.g. rhesus macaques and humanized mice) have been used as an alternative tool in 
HIV research to investigate antiretroviral pharmacology.16 Yet, the degree of correlation 
between human and animal tissue pharmacokinetics has yet to be fully characterized. 
Interspecies differences in MRP4 and BCRP drug transporter expression in mucosal tissues 
have been reported17, which could lead to markedly different antiretroviral tissue exposure. 
Therefore, in the absence of well-established models, pharmacokinetic characterization in 
human tissues is warranted. However, as previously discussed, quantifying tissue drug 
concentrations complicates study design.
We investigated whether mucosal fluids could be a pharmacokinetic surrogate for mucosal 
tissues, as they can be self-collected by study volunteers via direct aspiration of CVF or 
swab for RF and immediately stored at −20° to −70°C with no specimen processing 
required. This eliminates the risk of increased variability due to uncharacterized dilutions (as 
is the case for cervicovaginal lavage) or degradation of the analyte during processing. 
Furthermore, because these collection techniques are less invasive, fluid can be intensively 
sampled.
Herein we investigated the pharmacokinetics of mucosal fluid across 3 dosing levels for 4 
antiretrovirals and quantified the relationship between mucosal fluid and tissue drug 
concentration. In plasma, only emtricitabine met the pre-specified criteria for dose 
proportionality; however an exploratory ANOVA of dose-normalized AUC demonstrated no 
significant difference between the dosing groups for maraviroc, raltegravir, and emtricitabine 
(data not shown). These data suggest these antiretrovirals follow linear 
pharmacokinetics.18-21 We also noted a statistically significant relationship between dose 
and plasma exposure for the 4 antiretrovirals studied (r2 ≥0.64, p<0.01). We did not find 
evidence of dose proportionality in CVF but did note a linear relationship (r2 ≥0.23, p<0.05) 
between dose and exposure for all analytes except raltegravir. In RF we did not find 
evidence of dose proportionality, and only emtricitabine exposure exhibited a linear 
relationship with dose (r2 =0.27, p=0.011). The median rectal fluid AUC0-48hr for the 
maraviroc, raltegravir, and tenofovir in the 200% dosing groups was 38-93% lower than in 
the 100% dosing groups, suggesting that saturation occurs within lower gastrointestinal tract 
tissue and may be an important consideration in designing predictive models for drug 
concentrations.
In the female genital tract, we observed a stronger association between tissue and plasma 
concentration where plasma explained 14-51% more variability in tissue concentration 
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compared to CVF. Incorporating both plasma and CVF increased explained variability in 
tissue concentration by 4-10%. In the lower gastrointestinal tract, rectal tissue was more 
strongly associated with RF, which explained 31-90% more variability in tissue 
concentration compared to plasma. Incorporating both plasma and RF increased explained 
variability in tissue concentration by 8-19% for all antiretrovirals except tenofovir. For 
tenofovir, rectal tissue concentration was best predicted by RF alone. These data 
demonstrate the importance of incorporating both mucosal fluid and plasma in predictive 
models of mucosal tissue concentrations; but may also endorse prioritizing plasma for 
predictive models of female genital tract tissue or mucosal fluid for rectal tissue if resources 
are limited.
One limitation of this work is the small number of biopsy samples obtained (N=47 from 
each tissue type), and the presence of BLQ values. Ad hoc approaches where BLQ/BLD 
values are imputed based on the LLOQ have previously demonstrated bias in regression 
analyses.12 Using our extended statistical method to formally account for left censoring 
improved our regression models’ ability to explain variability in tissue concentrations 
compared to the ad hoc method (adjusted r2 values increased by 0.01 – 0.11). However, the 
small sample size limits the precision with which predictions can be made.
Our concentration data were collected from a relatively homogenous population of healthy, 
female volunteers at standardized points in their menstrual cycle. While concentration data 
for these drugs collected in the colorectal tissue of men and women have not demonstrated 
sex differences in concentrations, the relationship we observed for RF and lower 
gastrointestinal tract tissue concentrations should be confirmed in a male population. The 
delayed peak in rectal fluid also limited our ability to accurately determine AUC0-48hr as all 
4 antiretrovirals appear to be in the accumulation/distribution phase at 48 hours.
Although tissue biopsy homogenates provide an average mucosal tissue drug concentration 
across all cell types located within the biopsy, isolating clinically relevant, HIV target cells, 
from vaginal and cervical tissue biopsies has previously resulted in incomplete 
pharmacokinetic data sets due to small, inconsistent cell yields.22 Additionally, lipophilic 
compounds such as raltegravir and maraviroc quickly partition out of the intracellular space 
during ex vivo specimen processing, which may confound cellular drug concentration 
measurements.23,24 However, a linear relationship between isolated mucosal cells and tissue 
homogenate concentration have been previously reported25, suggesting that it is possible to 
impute cellular concentration data from whole tissue homogenates. Finally, given the 
inability to declare dose proportionality in CVF, or linearity in RF, it is important to note that 
the relationship we describe herein between fluid and tissue concentration might not extend 
past this 4-fold dosing range.
Our findings demonstrate strong relationships between plasma, mucosal fluid, and mucosal 
tissue drug concentrations for 4 antiretrovirals. These data suggest that plasma and mucosal 
fluid concentrations may be used to make qualitative inferences of tissue drug 
concentrations for the four antiretrovirals investigated (tenofovir disoproxil fumarate, 
emtricitabine, maraviroc, and raltegravir). These data could be used to optimize clinical trial 
design where a qualitative assessment of mucosal tissue drug concentrations is appropriate. 
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In studies requiring quantitative assessment of drug concentrations our data demonstrates the 
potential utility of intensively sampling mucosal fluids and plasma to supplement sparsely 
sampled tissue data.
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Figure 1. Concentration vs Time in Cervicovaginal Fluid
Median and 25th to 75th percentile cervicovaginal fluid concentrations are shown over 48 
hours following a single oral dose of emtricitabine (A), maraviroc (B), raltegravir (C) or 
tenofovir disoproxil fumarate (D) across a 4-fold dosing range. N=24 healthy female 
volunteers for maraviroc and tenofovir disoproxil fumarate, N=23 for emtricitabine and 
raltegravir. Values below the limit of quantification (BLQ) or detection (BLD) are displayed 
at 0.5 or 0.1 times the lower limit of quantification, respectively. Percent of concentration 
values in dataset that were BLQ/BLD are as follows: emtricitabine= 1.8/7.0%, 
maraviroc=8.0/12.2%, raltegravir=4.8/5.9%, and tenofovir=6.3/14.6%. Axis break applied at 
4 to 6 hours to better visualize early sampling time points.
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Figure 2. Concentration vs Time in Rectal Fluid
Median and 25th to 75th percentile rectal fluid concentrations are shown over 48 hours 
following a single oral dose of emtricitabine (A), maraviroc (B), raltegravir (C) or tenofovir 
disoproxil fumarate (D) across a 4-fold dosing range. N=24 healthy female volunteers for 
maraviroc and tenofovir disoproxil fumarate, N=23 for emtricitabine and raltegravir. Values 
below the limit of quantification (BLQ) or detection (BLD) are displayed at 0.5 or 0.1 times 
the lower limit of quantification, respectively. Percent of concentration values in dataset that 
were BLQ/BLD: emtricitabine= 5.4/0.7%, maraviroc=4.8/9.0%, raltegravir=1.8/0.3%, and 
tenofovir=9.3/11.7%. Axis break applied at 4 to 6 hours to better visualize early sampling 
time points.
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Figure 3. Female Genital Tract Tissue vs Plasma and Fluid
Paired female genital tract tissue vs plasma (left panel) or cervicovaginal fluid (CVF; right 
panel) for emtricitabine (A), maraviroc (B), raltegravir (C) and tenofovir (D). N=24 paired 
concentrations for maraviroc and tenofovir or 23 for emtricitabine and raltegravir. ○ 
represents concentration pairs with 2 detectable concentrations; ▽ represents concentration 
pairs where the X variable is left-censored (i.e. below the limit of quantification or 
detection); □ represents concentration pairs where the Y variable (tissue concentration) is 
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left-censored. The regression line, adjusted r2 and p values from separate linear regression 
analyses for CVF and plasma vs tissue concentration is included in each panel.
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Figure 4. Lower Gastrointestinal Tract Tissue vs Plasma and Fluid
Paired lower gastrointestinal tract tissue vs plasma (left panel) or rectal fluid (RF; right 
panel) for emtricitabine (A), maraviroc (B), raltegravir (C) and tenofovir (D). N=24 paired 
concentrations for maraviroc and tenofovir or 23 for emtricitabine and raltegravir. ○ 
represents concentration pairs with two detectable concentrations; ▽ represents 
concentration pairs where the X variable is left-censored (i.e. below the limit of 
quantification); □ represents concentration pairs where the Y variable (tissue concentration) 
is left-censored. △ represents concentration pairs where the Y variable (tissue concentration) 
Cottrell et al. Page 15
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
is right censored. The regression line, adjusted r2 and p values from the separate linear 
regression analyses for RF and plasma vs tissue concentration is included in each panel.
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Table 1
Antiretroviral Exposure vs Dose Relationship
Plasma Cervicovaginal Fluid Rectal Fluid
Analyte β1a (90%CI) r
2
 (p value) β1 (90%CI) r2 (p value) β1 (90%CI) r2 (p value)
Tenofovir 0.76 (0.62, 0.90) 0.80 (<0.001) 1.21 (0.79, 1.63) 0.53 (<0.001) 1.21 (−0.42, 2.84) 0.07 (0.22)
Maraviroc 1.24 (0.98, 1.51) 0.74 (<0.001) 1.74 (1.28, 2.21) 0.66 (<0.001) 1.01 (−0.40, 2.42) 0.06 (0.23)
Emtricitabine 0.85 (0.72 0.99)b 0.85 (<0.001) 0.47 (0.15, 0.79) 0.23 (0.021) 1.69 (0.64, 2.75) 0.27 (0.011)
Raltegravir 0.77 (0.55, 0.99) 0.64 (<0.001) 0.39 (−0.10, 0.87) 0.08 (0.186) 1.35 (0.06, 2.63) 0.13 (0.085)
CI: Confidence interval
aSlope of regression line for natural log-transformed AUC0-48hr vs dose (β1)=1 indicates perfect dose proportionality.
b
Dose proportionality declared (90% CI within 0.64, 1.36).
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